61results about How to "Good physiological compatibility" patented technology

The invention relates to a mixture composition comprising rhamnolipids, to a process for its preparation, to its use for producing formulations and to formulations comprising this mixture composition.

The invention belongs to the technical field of medicine, and relates to mesoporous carbon and a preparation process thereof, and an application of the mesoporous carbon in insoluble drug delivery systems. According to the process, a hard template method is adopted to prepare the mesoporous carbon, wherein mesoporous silica is adopted as a template, sucrose is adopted as a carbon source, and sulfuric acid is adopted as a catalyst to prepare the mesoporous carbon, wherein the prepared mesoporous carbon has characteristics of large specific surface area, stable property, no toxic-side effect and good biocompatibility, and can be adopted as a insoluble drug carrier. According to the present invention, a solvent method and a melting method are adopted to carry out drug embedding and adsorption so as to achieve uniform dispersion of the drug in the pores and on the surface of the carrier; with the drug delivery system, water solubility of insoluble drugs can be significantly enhanced, and in vitro dissolution rate and oral bioavailability can be improved.

The invention belongs to the technical field of medicaments and relates to porous hydroxyapatite, a preparation process thereof and application thereof to difficultly soluble medicament feeding system. A hydrothermal template method is adopted in the process, namely, a triblock copolymer F127 and hexadecyl trimethyl ammonium bromide (CTAB) serve as templates to prepare the porous hydroxyapatite under a hydrothermal condition. The porous hydroxyapatite is large in specific surface area, stable in performance and good in biocompatibility, does not have toxic or side effects, has a plurality of hydrophilic groups on the surface, and is suitable to be used as a carrier of a difficultly soluble medicament. The medicament is embedded and absorbed by a solvent method or a melting method, so that the medicament is uniformly dispersed in the aperture of the carrier and on the surface of the carrier. By the system, the water-solubility of the difficultly soluble medicament can be obviously improved, the dissolution speed is improved, and the bioavailability of the medicament is improved when the medicament is orally taken.

Pharmaceutical formulations and methods of producing and using the same are described and claimed. The formulations are dispersions of phospholipids and one or more pharmacologically active compounds, pharmaceutically acceptable salts thereof, or prodrugs thereof. In specific embodiments, the pharmaceutically active compounds are ansamycins and the overall formulation is substantially devoid of medium and long chain triglycerides.

The invention relates to an oil-in-water type garlicin-garlic oil sub-microemulsion distributed in an inner phase (oil phase) as well as a method for preparing the same. The formulation of the emulsion contains 0.5 to 3 weight portions of garlicin or garlic oil as a medicament, and the garlicin or the garlic oil is added with a pharmaceutic adjuvant and is prepared into a garlicin sub-microemulsion or a garlic oil sub-microemulsion, wherein the pharmaceutic adjuvant comprises 5 to 20 weight portions of injection oil, 0.2 to 5 weight portions of emulsifier, 0 to 5 weight portions of coemulsifier, 0.5 to 3 weight portions of isoosmotic adjusting agent, a proper amount of antioxidant, a proper amount of pH regulator and a proper amount of injection water. The invention discusses the medicament distribution in oil, an oil/water interfacial film and water when the garlicin or the garlic oil is in an oil-in-water type dispersion system macroscopically and microscopically; more than 98 percent of the medicaments are enwrapped in the oil phase and the medicament free in the water phase is less than 1 percent; and the problem of a garlicin or garlic oil intravenous injection preparation for a hydrophobic dug is solved, the stability of an emulsion thereof is improved, and the vascular stimulation in an intravenous injection is reduced, thus the adaptability of a patient is greatly improved. The oil-in-water type garlicin-garlic oil sub-microemulsion can be applied to the adjuvant therapy of bacteria resistance, cardiovascular and cerebrovascular diseases and tumors.

The invention belongs to the field of medicine technology, and relates to a preparation method of mesoporous titanium dioxide with high biological compatibility and a controllable structure and application of the mesoporous titanium dioxide as a hard soluble drug carrier. The method adopts a soft template method, namely, adopts a surfactant as a structure guiding agent, isopropyl titanate as titanium source, and double distilled water as a reaction rate modifier to prepare the mesoporous titanium dioxide having different mesoporous passage structures. The prepared mesoporous titanium dioxide is of large specific surface area, chemical stability, non-toxic effect, no side effect and good biocompatibility, and is suitable for being used as the hard soluble drug carrier. The application of the titanium dioxide as the hard soluble drug carrier can lay a theoretical foundation for uses of multivariant functional carriers. The method adopts a solvent method and a fusion method to perform embedding and adsorption on a drug so as to uniformly disperse the drug inside the mesoporous or on surface of the carrier. The drug carrier system can assist in significantly enhancing water solubility of a hard soluble drug and improving dissolution rate in vitro and oral bioavailability.

The invention relates to an atorvastatin calcium nano-lipid carrier and a preparation method thereof. The atorvastatin calcium nano-lipid carrier comprises the following components: 1 wt% to 2 wt% of atorvastatin calcium, 12 wt% to 24 wt% of a lipid material, 10 wt% to 30 wt% of phospholipid and 30 wt% to 50 wt% of an emulsifier. The preparation method comprises the following steps: weighing the atorvastatin calcium, the lipid material and the phospholipid, ultrasonically dissolving in an organic solvent, heating to 60-75 DEG C in a water bath, and using an obtained product as an organic phase; dissolving the emulsifier in water, heating to 60-75 DEG C in the water bath, and using an obtained product as a water phase; dropwise adding the organic phase into the water phase stirred at the speed of 90-1,200 r/min, continuously stirring for fully volatilizing the organic solvent, and concentrating to form a primary emulsion; pouring the primary emulsion into ice water with the volume being 2-5 times that of the primary emulsion, and continuously stirring and solidifying in an ice bath to obtain the atorvastatin calcium nano-lipid carrier. The atorvastatin calcium nano-lipid carrier is internally degradable and high in encapsulation efficiency; after drugs are prepared into nano-lipid carriers, the stability, the water solubility and the bioavailability of the drugs can be improved.

A glabridin-cladded nano solid lipid carrier contains 0.02-8% of glabridin, 2-20% of a solid emulsifier, 2-15% of solid lipid, 1-15% of liquid lipid, 2-10% of polyols, 0.5-5% of phospholipid, 0.02-1% of inorganic salt, 0.01-0.8% of a preservative and deionized water. The invention further provides a preparation method of the glabridin-cladded nano solid lipid carrier. The stability of the glabridin is improved by the glabridin-cladded nano solid lipid carrier, the infiltration of the glabridin into the skin is promoted, and the skin whitening and anti-oxidation effects are improved.

A lipid nanoparticle of zedoary oil used for preparing solid, liquid, injection, ointment, suppository, film, aerosol, etc is prepared from zedoary oil, medicinal phosphatide, emulsifier, solid lipid, liquid lipid and deoxidant through multiple methods.

The invention discloses a preparation method of a textile electrode material and the textile electrode material. The preparation method comprises the steps that firstly, pretreated fabric is soaked ina dopamine hydrochloride solution, and polydopamine coated fabric is obtained; then, the polydopamine coated fabric is soaked in a silver-ammonia solution, a glucose solution is added after a certainperiod of time, and a silver-plated fabric is obtained; the silver-plated fabric is subjected to chlorination treatment in a sodium chloride solution through an electrochemical method, and a silver-silver chloride composite coating fabric is formed; finally, the silver-silver chloride composite coating fabric is modified in a conductive polymer monomer solution through an electrochemical method,and the silver-silver chloride-conductive polymer composite coating fabric is obtained. The surface specific resistance of the textile electrode material is 0.01-5 omega, the polarization impedance ina 0.9% sodium chloride solution is 10-1000 omega, the skin interface impedance is 1K omega-100M omega at 1Hz, and the phase angle variation within the frequency range of 0.5-50Hz is 0-30 degrees.

The invention provides a hydrodynamic pressure suspension double-flow pump, relating to an impeller ultra-small pump which has no external mechanism axis and is driven magnetically. The pump comprises two mutually separate flowing channels; each flowing channel consists of an inlet, an impeller, a pressure water chamber and an outlet; and the geometrical parameters of the flowing channels are the same or different; a stator of the pump is embedded in a pump shell, a permanent magnet is embedded in a rotor; and the stator and the permanent magnet are arranged opposite along a radial direction; a radial gap is formed between the internal surface of the pump shell and the external surface of the rotor, so that liquid hydrodynamic support for restricting axial movement is formed during normal operation of the pump; an axial gap is formed between the front cover plate of each impeller and the corresponding pump cover, so that liquid hydrodynamic support for restricting rotor axial movement is formed during the normal operation of the pump. In such a way, the rotor can be suspended in the pump cavity during normal operation. The pump provided by the invention can be used for meeting double-flow use requirement of different flows and pressures, and good flowing condition can be effectively and favorably formed in the internal cavity of the pump shell, and moreover, the operation reliability of the pump can be improved.

The invention relates to glycyrrhetinic acid solid lipid nanoparticles and a preparation method for the same, belonging to the field of medicinal preparation. The main ingredients of the glycyrrhetinic acid solid lipid nanoparticles disclosed by the invention comprise active raw material glycyrrhetinic acid, medicinal phospholipid, a lipid material and a surfactant. The glycyrrhetinic acid solid lipid nanoparticle solution and the freeze-dried powder injection thereof prepared by the preparation method disclosed by the invention are small in particle diameter, high in entrapment efficiency, good in stability and capable of being used for a plurality of administration routes such as oral administration and injection administration. The glycyrrhetinic acid solid lipid nanoparticles disclosed by the invention can reduce dosage, enhance curative effect and reduce the toxic and side effects of medicine, as well as are suitable for treating a plurality of diseases such as hepatitis, liver cancer, lung cancer, ovarian cancer, gastritis, gastric cancer, leukaemia and aids.

The invention discloses a Decitabine sustained release microsphere, which comprises Decitabine and a carrier material, wherein the weight percentage of the Decitabine and the carrier material is 1-8%, the partical size of the Decitabine sustained release microsphere is below 10 mu m, and the entrapment rate of the Decitabine sustained release microsphere is more than 75%. The Decitabine sustainedrelease microsphere provided by the invention has higher loading rate, no in-vivo burst effect, stable blood concentration, and no drug release delivery deadtime, thus greatly reducing clinical interval of drug administration, reducing dosage, improving compliance of patients, and reducing hazard rating of adverse reaction.

The invention relates to a skin care product containing a biological buffering agent. The product includes microbial fermentation product extracts, and is characterized by further including the biological buffering agent with a mass percentage of 0.1-3.0%. The skin care product has the advantages that: the pH value of the product drifts in a small amplitude, the pH value stabilizes at 6.0-8.0 in three years after preparation of the skin care product, good protection is applied on the microbial fermentation product extracts added in the product, the microbial fermentation product extracts are not easy to be hydrolyzed, and anti-aging effects of the product lasts a long time.

The invention belongs to the technical field of medicines, and in particular relates to lactoferrin modified solid lipid nanoparticles, as well as a preparation method and application thereof. The lactoferrin modified solid lipid nanoparticles are characterized in that lactoferrin is modified on the surfaces of solid lipid nanoparticles. The lactoferrin modified solid lipid nanoparticles can wrap medicines therein and can be used as a medicine transfer carrier. The preparation method disclosed by the invention comprises the following steps: synthesising mal-sac-PEG-MS through DCC dehydration reaction, and preparing a nanosuspension by using mal-sac-PEG-MS; then, carrying out lactoferrin sulfhydrylation (Lf-SH) by virtue of a Traut's agent, adding Lf-SH into the nanosuspension, and stirring at a room temperature to carry out protein modification. The lactoferrin modified solid lipid nanoparticles disclosed by the invention have good particle size, Zeta potential and stability. Experimental results show that the lactoferrin modified solid lipid nanoparticles disclosed by the invention are capable of transferring model medicines, such as loperamide and coumarin 6, into brain.

The invention belongs to the technical field of bioengineering and discloses a polyglutamic acid and human epidermal growth factor nano-liposome and a preparation method thereof. The nano-liposome comprises high molecular weight polyglutamic acid, low molecular weight polyglutamic acid, a human epidermal growth factor and a liposome membrane material. According to the polyglutamic acid and human epidermal growth factor nano-liposome, the high molecular weight polyglutamic acid and the low molecular weight polyglutamic acid are compounded with the human epidermal growth factor and the preservative-free nano-liposome is prepared by utilizing a bacterium-inhibition effect of epsilon-polylysine; the nano-liposome has an addition and multiplying effect on skin repairing; the transdermal performance and skin absorption rate of active components are greatly improved; the nano-liposome has stable performance, good utilization compatibility and relatively high encapsulation rate.

The invention relates to the field of therapeutic antibodies, in particular relates to an anti-programmed cell death-ligand 1 (PD-L1) antibody preparation. The preparation comprises an anti-PD-L1 antibody, a buffer solution and sodium chloride, and added sugar and/or sugar alcohols are absent. The anti-PD-L1 antibody preparation of the invention can maintain antibody stability after long-term storage. In addition, the invention further relates to a use of the anti-PD-L1 antibody preparation in preparing drugs used for the prevention and/or treatment and/or adjuvant treatment and/or diagnosis of tumors or anemia

The invention discloses a methyl methacrylate block copolymer and a preparation method thereof. The copolymer is polymethylmethacrylate-b-polyacrylic acid-2-ethyl ester serving as an AB block copolymer. The polymethylmethacrylate-b-polyacrylic acid-2-ethyl ester is synthesized by a fractional step method which comprises the following steps of: obtaining end group chlorine-containing polymethylmethacrylate by adopting azodiisobutyronitrile as an initiator and ferric trichloride/triphenylphosphine as a catalytic system through the reverse atom transfer radical polymerization of methyl methacrylate; and obtaining the two-block polymer polymethylmethacrylate-b-polyacrylic acid-2-ethyl ester by adopting the end group chlorine-containing polymethylmethacrylate as the macromolecular initiator and the ferric trichloride/triphenylphosphine as the catalytic system through the atom transfer radical polymerization. The block copolymer has the structure shown as the description.

The invention discloses a preparation method and application of reduced glutathione lipidosome, relates to a preparation method and application of lipidosome, and aims at solving the technical problem of low inclusion rate of the lipidosome prepared by the existing method. The method comprises the following steps: 1, weighing soya bean lecithin and fatty acid glycerides, dissolving into absolute ethyl alcohol, and heating in a water bath to prepare an oil phase; 2, weighing reduced glutathione and a surfactant to be dissolved into distilled water, and heating in the water bath to prepare a water phase; 3, mixing the prepared oil phase with the water phase, emulsifying, carrying out vacuum rotary evaporation to remove absolute ethyl alcohol, adding distilled water, pre-cooling after ice-bath, and then carrying out freeze drying to obtain lipidosome powder. The reduced glutathione lipidosome disclosed by the invention is applied to intravenous injection, oral medication, transdermal drug delivery, and a drug delivery system for the lung and eyes. The encapsulation efficiency of the reduced glutathione lipidosome disclosed by the invention is 68.15%+/-1.53%. The preparation method is applied to the field of preparation of the lipidosome.